”ρ“™ƒ‚ƒ‹ PSA(‘O—§‘B“ΑˆΩRŒ΄)‘ͺ’θŒn‚πRƒtƒŠ[ PSA ƒ‚ƒmƒN
ƒ[ƒiƒ‹R‘Μ“Y‰Α‚Ι‚ζ‚θ“™ƒ‚ƒ‹‘ͺ’θŒn‚Ι‰ό‘P‚·‚ιŽŽ‚έ


–؁@‘Ί@Œb@”ό*1@Ό@–{@‹±@ˆκ*2@²@Žη@—F@”Ž*3
@@@@@@@@@@@@@@@@@@@@@@
Improvement of Total Prostate Specific Antigen(PSA) Assay from
the "Skewed Molar-Response" to the "Equimolar-Response" by
Utilizing anti Free-PSA Monoclonal Antibodies

Emi KIMURA*1, Kyoichi MATSUMOTO*2 and Tomohiro SAMORI, MD*3

Prostate specific antigen(PSA) is widely used as a marker for screening and monitoring prostate cancer. However, there are several assay methods, which often give different PSA values for the same patient sample. A possible cause of these discrepancies might be the varied immunoreactivity with free-PSA and complex-PSA among methods.
This study revealed that pre-treatment of samples with anti-free-PSA monoclonal antibodies improved polyclonal antibodies-based non equimolar PSA assay to equimolar assay.
This might be achieved by that the monoclonal antibodies bind to free-PSA and then change its reactivities with polyclonal antibodies to those similar to complex-PSA.
[Rinsho Byori 50 : 202`206, 2002]

*1Japan Clinical Laboratories, Inc. Kuze-gun, Kyoto-pref. 613-0046

yKey Wordszprostate specific antigenFPSA(‘O—§‘B“ΑˆΩRŒ΄)Cfree-PSA(—V—£Œ^ PSA)Ccomplex-PSA(Œ‹‡Œ^ PSA)Cenzyme-linked immunosorbent assayFELISA(y‘f–Ζ‰u‘ͺ’θ–@)Cequimolar assay(“™ƒ‚ƒ‹”½‰žŒn)

Žσ•t2001”N8ŒŽ29“ϊEŽσ—2001”N11ŒŽ15“ϊ
*1`3‡M“ϊ–{ˆγŠw—Տ°ŒŸΈŒ€‹†ŠŠwpŒ€‹†‰Ϋ(§613-0046 ‹ž“s•{‹v’ŒS‹vŒδŽR’¬‘ε‹΄•Σ16-10)

E-mail :e.kimura@lnm.jcl.co.jp